新奥尔良神经内分泌肿瘤专科中心（NOLANETS）在 COVID-19 大流行期间对患者护理的响应。
A Neuroendocrine Tumor Specialty Center in New Orleans' (NOLANETS) Response to Patient Care During the COVID-19 Pandemic.
机构信息
Ochsner Medical Center, Kenner, Louisiana, USA.
Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, Louisiana, USA.
出版信息
Oncologist. 2020 Jul;25(7):548-551. doi: 10.1634/theoncologist.2020-0279. Epub 2020 May 21.
Abstract
This commentary outlines the steps taken by the New Orleans Louisiana Neuroendocrine Tumor Specialists to minimize the risk of patient exposure to SARS‐CoV‐2 but to continue to provide safe, high‐quality care during the COVID‐19 pandemic.
摘要
本评论概述了新奥尔良路易斯安那州神经内分泌肿瘤专家为尽量降低患者暴露于 SARS-CoV-2 风险而采取的步骤，但仍要在 COVID-19 大流行期间提供安全、高质量的护理。
相似文献
1
A Neuroendocrine Tumor Specialty Center in New Orleans' (NOLANETS) Response to Patient Care During the COVID-19 Pandemic.新奥尔良神经内分泌肿瘤专科中心（NOLANETS）在 COVID-19 大流行期间对患者护理的响应。
Oncologist. 2020 Jul;25(7):548-551. doi: 10.1634/theoncologist.2020-0279. Epub 2020 May 21.
2
Ensuring continuity of care for children with inherited metabolic diseases at the time of COVID-19: the experience of a metabolic unit in Italy.在新冠疫情期间确保遗传性代谢疾病患儿的连续护理：意大利一个代谢病科室的经验
Genet Med. 2020 Jul;22(7):1178-1180. doi: 10.1038/s41436-020-0831-4. Epub 2020 May 15.
3
Cancer Patient Care during COVID-19.2019冠状病毒病疫情期间的癌症患者护理
Cancer Cell. 2020 Jun 8;37(6):749-750. doi: 10.1016/j.ccell.2020.05.006. Epub 2020 May 14.
4
Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.COVID-19 疫情中心的乳腺癌护理的个性化风险-效益比调整。
Oncologist. 2020 Jul;25(7):e1013-e1020. doi: 10.1634/theoncologist.2020-0316. Epub 2020 May 26.
5
Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change?新冠疫情后时代的临床研究中断：这场大流行会带来改变吗？
ESMO Open. 2020 Oct;5(5):e000924. doi: 10.1136/esmoopen-2020-000924.
6
Teleoncology or telemedicine for oncology patients during the COVID-19 pandemic: the new normal for breast cancer survivors?疫情期间肿瘤患者的远程肿瘤学或远程医疗：乳腺癌幸存者的新常态？
Future Oncol. 2020 Oct;16(28):2191-2195. doi: 10.2217/fon-2020-0714. Epub 2020 Aug 28.
7
Could we benefit from oral self-examination during the COVID-19 pandemic?在新冠疫情期间，我们能从口腔自我检查中获益吗？
Oral Oncol. 2020 Aug;107:104840. doi: 10.1016/j.oraloncology.2020.104840. Epub 2020 Jun 4.
8
Digitalized Adaptation of Oncology Trials during and after COVID-19.COVID-19期间及之后肿瘤试验的数字化适应
Cancer Cell. 2020 Aug 10;38(2):148-149. doi: 10.1016/j.ccell.2020.06.018. Epub 2020 Jul 6.
9
A recommendation for IVF lab practice in light of the current COVID-19 pandemic.鉴于当前的COVID-19大流行对体外受精实验室操作的建议。
J Assist Reprod Genet. 2020 Jul;37(7):1543. doi: 10.1007/s10815-020-01841-3. Epub 2020 May 28.
10
The COVID-19 pandemic and the Tata Memorial Centre response.新冠疫情与塔塔纪念中心的应对措施。
Indian J Cancer. 2020 Apr-Jun;57(2):123-128. doi: 10.4103/ijc.IJC_250_20.
引用本文的文献
1
Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study.2019 年冠状病毒病患者的神经内分泌肿瘤：INTENSIVE 研究的初步结果。
Eur J Cancer. 2021 Sep;154:246-252. doi: 10.1016/j.ejca.2021.06.029. Epub 2021 Jun 30.
2
Impact of the COVID-19 pandemic on neuroendocrine tumour services in England.新冠疫情对英格兰神经内分泌肿瘤服务的影响。
Endocrine. 2021 Jan;71(1):14-19. doi: 10.1007/s12020-020-02564-2. Epub 2021 Jan 5.
3
Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era.《COVID-19 时代胃肠胰和胸部（类癌）神经内分泌肿瘤患者管理的实用建议》
Eur J Cancer. 2021 Feb;144:200-214. doi: 10.1016/j.ejca.2020.11.037. Epub 2020 Dec 25.
4
Professional Assessment of the Impact of COVID-19 on Handling NET Patients.新型冠状病毒肺炎（COVID-19）对神经内分泌肿瘤（NET）患者治疗影响的专业评估
J Clin Med. 2020 Nov 11;9(11):3633. doi: 10.3390/jcm9113633.
本文引用的文献
1
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
2
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs).卡培他滨与替莫唑胺（CAPTEM）治疗晚期神经内分泌肿瘤（NENs）的疗效
Cancers (Basel). 2020 Jan 14;12(1):206. doi: 10.3390/cancers12010206.
3
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.神经内分泌肿瘤的通用分类框架：国际癌症研究机构（IARC）和世界卫生组织（WHO）专家共识建议。
Mod Pathol. 2018 Dec;31(12):1770-1786. doi: 10.1038/s41379-018-0110-y. Epub 2018 Aug 23.
4
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.北美神经内分泌肿瘤学会关于中肠神经内分泌肿瘤监测与医学管理的共识指南
Pancreas. 2017 Jul;46(6):707-714. doi: 10.1097/MPA.0000000000000850.
5
Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.生长抑素类似物在散发性、进展性、转移性肺类癌中的抗肿瘤活性
Eur J Cancer. 2017 Apr;75:259-267. doi: 10.1016/j.ejca.2016.11.034. Epub 2017 Feb 27.
6
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
7
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.奥曲肽长效注射剂（LAR）对转移性中肠神经内分泌肿瘤患者肿瘤生长控制效果的安慰剂对照、双盲、前瞻性、随机研究（PROMID）：长期生存结果
Neuroendocrinology. 2017;104(1):26-32. doi: 10.1159/000443612. Epub 2016 Jan 6.
8
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.依维莫司治疗晚期肺或胃肠道无功能性神经内分泌肿瘤（RADIANT-4）：一项随机、安慰剂对照的3期研究。
Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.
9
The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.高级别（世界卫生组织G3级）胰腺神经内分泌肿瘤类别在形态学和生物学上具有异质性，包括高分化和低分化肿瘤。
Am J Surg Pathol. 2015 May;39(5):683-90. doi: 10.1097/PAS.0000000000000408.
10
Everolimus for advanced pancreatic neuroendocrine tumors.依维莫司治疗晚期胰腺神经内分泌肿瘤。
N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.
Zotero 插件